Gateway Wealth Partners LLC Purchases 33,532 Shares of Pfizer Inc. $PFE

Gateway Wealth Partners LLC grew its stake in shares of Pfizer Inc. (NYSE:PFE) by 333.4% in the first quarter, according to the company in its most recent filing with the SEC. The firm owned 43,591 shares of the biopharmaceutical company’s stock after acquiring an additional 33,532 shares during the quarter. Gateway Wealth Partners LLC’s holdings in Pfizer were worth $1,224,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Brighton Jones LLC boosted its position in shares of Pfizer by 1,282.4% during the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock worth $17,677,000 after acquiring an additional 618,117 shares in the last quarter. Revolve Wealth Partners LLC raised its position in Pfizer by 12.5% during the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock valued at $498,000 after purchasing an additional 2,087 shares in the last quarter. United Bank lifted its stake in Pfizer by 12.4% during the second quarter. United Bank now owns 58,087 shares of the biopharmaceutical company’s stock worth $1,408,000 after purchasing an additional 6,415 shares during the last quarter. Sei Investments Co. lifted its stake in Pfizer by 31.5% during the second quarter. Sei Investments Co. now owns 2,635,691 shares of the biopharmaceutical company’s stock worth $63,889,000 after purchasing an additional 631,523 shares during the last quarter. Finally, HUB Investment Partners LLC grew its holdings in shares of Pfizer by 45.3% during the 2nd quarter. HUB Investment Partners LLC now owns 102,327 shares of the biopharmaceutical company’s stock valued at $2,480,000 after purchasing an additional 31,896 shares during the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages recently commented on PFE. Cantor Fitzgerald reissued a “neutral” rating and issued a $27.00 price objective on shares of Pfizer in a research note on Monday, July 6th. Morgan Stanley boosted their target price on shares of Pfizer from $27.00 to $28.00 and gave the stock an “equal weight” rating in a research note on Friday, April 10th. Royal Bank Of Canada upgraded shares of Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 price target for the company in a report on Tuesday, June 9th. JPMorgan Chase & Co. dropped their price target on Pfizer from $30.00 to $28.00 and set a “neutral” rating for the company in a research note on Wednesday, July 8th. Finally, Citigroup raised their price objective on Pfizer from $26.00 to $27.00 and gave the company a “neutral” rating in a report on Wednesday, April 29th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fourteen have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $28.50.

Pfizer Price Performance

Shares of PFE opened at $25.25 on Wednesday. The business has a 50-day moving average of $25.09 and a 200-day moving average of $26.17. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.25 and a quick ratio of 0.94. The company has a market capitalization of $143.88 billion, a price-to-earnings ratio of 19.27 and a beta of 0.35. Pfizer Inc. has a 1 year low of $23.11 and a 1 year high of $28.75.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, beating the consensus estimate of $0.72 by $0.03. The business had revenue of $14.45 billion for the quarter, compared to analysts’ expectations of $13.84 billion. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The firm’s revenue was up 5.4% on a year-over-year basis. During the same period in the prior year, the business posted $0.92 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, equities research analysts anticipate that Pfizer Inc. will post 2.96 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.8%. The ex-dividend date of this dividend is Friday, July 24th. Pfizer’s dividend payout ratio is currently 131.30%.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Analysts expect Pfizer to beat second-quarter earnings estimates, supported by favorable earnings expectations and improving revenue trends. The prospect of another earnings surprise may be encouraging investors ahead of the report. Pfizer Expected to Beat Earnings Estimates
• Positive Sentiment: Pfizer completed a Phase 1 study evaluating the tablet formulation of ibuzatrelvir, an antiviral candidate. While early-stage data do not establish commercial success, the update represents progress in Pfizer’s pipeline and could support longer-term growth expectations. Pfizer Fine Tunes Ibuzatrelvir Tablet
• Positive Sentiment: The FDA’s priority review of TALZENNA in combination with XTANDI for an earlier prostate-cancer setting could expand Pfizer’s oncology franchise. Investors may view the opportunity as a potential offset to declining legacy and COVID-related products. FDA Priority Review of TALZENNA
• Positive Sentiment: Several market commentaries highlighted Pfizer’s discounted valuation and argued that its patent-cliff concerns may already be reflected in the share price. This value-investing narrative likely contributed to buying interest. Pfizer Valuation and Patent Cliff Analysis

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.